Fig. 2: Insulin requirements, beta cell function, and CHGA over 2 years of T1D treatment with verapamil. | Nature Communications

Fig. 2: Insulin requirements, beta cell function, and CHGA over 2 years of T1D treatment with verapamil.

From: Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

Fig. 2

Changes over time in serum CHGA as assessed by ELISA (F4,19 = 8.723, P = 0.0003) (a), C-peptide AUC (F4,19 = 4.346, P = 0.012) (b), daily insulin dose (F4,23 = 3.094, P = 0.036) (c) and blood glucose control as assessed by HbA1C (d) in subjects with T1D receiving verapamil for 2 years (Verapamil; n = 5), discontinuing verapamil after the first year (Disc V; n = 4), or not taking any verapamil (Control; n = 6). Means ± SEM are shown, two-way repeated-measures ANOVA. Subject characteristics of these subgroups are shown in Supplementary Table 4. Source data are provided as a Source Data file.

Back to article page